Advertisement

Topics

Alkermes Depression Drug Review Goes Ahead After FDA About-Face

12:29 EDT 16 Apr 2018 | Xconomy

Less than a month after the FDA refused to review Alkermes’ new drug application for the company’s depression drug, the agency has changed its mind, according to a statement from the company. After it “clarified certain aspects of the NDA submission”, Alkermes said Monday that the FDA will now accept the application without requiring additional […]

Original Article: Alkermes Depression Drug Review Goes Ahead After FDA About-Face

NEXT ARTICLE

More From BioPortfolio on "Alkermes Depression Drug Review Goes Ahead After FDA About-Face"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...